MEACOR

Meacor is a pioneering medical device company based in Irvine, California and Westmount, Quebec, specializing in innovative minimally invasive solutions for valvular heart disease.

We develop and refine novel technologies to address the significant unmet clinical need for improved treatment options for patients with mitral and tricuspid valve regurgitation. Our core focus is on transcatheter interventions, offering a less invasive alternative to traditional open-heart surgery.

CryoCinch, our flagship product, represents a groundbreaking anchoring catheter system utilizing on-demand cryoadhesion, replicating the gold standard of annuloplasty without the need for open-heart surgery. Developed by a team of experienced engineers and surgeons, Meacor is committed to advancing cardiovascular care through technological innovation. We’ve been recognized for our innovation, including winning the McGill Dobson Cup Start-up competition and receiving the William and Rhea Seath Awards in Engineering Innovation.

Our team, led by Toufic Azar, PhD, and Dr. Renzo Cecere, M.D., combines deep expertise in mechanical engineering, surgical practice, and business leadership to drive the development and commercialization of our technologies. We are proud to be supported by a strong board of advisors and investors dedicated to our mission of healthier hearts.